Table 3.
Risk factors for impaired work performance or absence from work due to side effectsafter the second dose of BNT162b2 and the first dose of ChAdOx1 vaccination.
| Impaired Work Performance or Absence on Work (n = 706) | No Impact (n = 1401) | Odds Ratio (95% CI) | Adjusted Odds Ratio (95% CI) | |
|---|---|---|---|---|
| Gender, female vs. male |
549 (77.8) | 969 (69.2) | 1.56 (1.26–1.92) | 1.38 (1.11–1.72) |
| Vaccine | ||||
| ChAdOx1 #1 vs. BNT162b2 #2 |
454 (64.3) | 686 (49.0) | 1.88 (1.56–2.26) | 2.05 (1.69–2.49) |
| Age | ||||
| 20–29 year-old vs. ≥30 year-old |
286 (40.5) | 447 (31.9) | 1.45 (1.21–1.75) | |
| 20–39 year-old vs. ≥40 year-old |
524 (74.2) | 761 (54.3) | 2.42 (1.99–2.95) | 2.54 (2.06–3.12) |
| 20–49 year-old vs. ≥50 year-old |
641 (90.8) | 1052 (75.1) | 3.72 (2.47–4.34) | |
| 20–59 year-old vs.≥60 year-old |
699 (99.0) | 1308 (93.4) | 7.10 (3.28–15.39) | |
| Previous confirmed SARS-CoV-2 infection vs. No |
5 (0.7) | 27 (1.9) | 0.36 (0.14–0.95) | 0.37 (0.14–1.01) |
| History of allergy | ||||
| To any drug or food vs. No |
52 (7.4) | 78 (5.6) | 1.35 (0.94–1.94) | |
| To any vaccine vs. No |
12 (1.7) | 10 (0.7) | 2.41 (1.03–5.59) | 2.26 (0.94–5.41) |
| History of anaphylaxis | ||||
| To any drug or food vs. No |
5 (0.7) | 8 (0.6) | 1.24 (0.41–3.81) | |
| To any vaccine vs. No |
4 (0.6) | 3 (0.2) | 2.66 (0.59–11.90) | |
| Pre-vaccination medication | ||||
| Acetaminophen vs. No |
158 (22.5) | 232 (16.6) | 1.47 (1.17–1.84) | 1.23 (1.00–1.60) |
| NSAID vs. No |
16 (2.3) | 40 (2.9) | 0.79 (0.44–1.42) | |
| Anti-histamines vs. No |
7 (1.0) | 4 (0.3) | 3.49 (1.02–11.99) | 4.38 (1.24–15.49) |
Data are presented as numbers (%) of respondents. BNT162b2 #2, the second dose of BNT162b2; ChAdOx1 #1, the first dose of ChAdOx1; 95% CI, 95% confidence interval; NSAID, non-steroid anti-inflammatory drug.